As every year, the winter season is synonymous of influenza viruses causing health problems and significant economic losses for public and private companies. One small, but not negligible, percentage will incur in complications and, potentially, there will also be an increase in mortality for new-borns and elderly patients, caused by the same virus. The vaccine against the seasonal influenza virus strain protects with an effectiveness estimated between 75 and 80 percent – therefore quite good – but not complete.
Elisa Vicenzi obtained a Degree in PHarmacy in 1980 at the University of Ferrara and, in 1981, has started her research activity in the Thrombosis and Hemostasis Laboratory directed by Maria Benedetta Donati, at the Mario Negri Institute in Milan. In 1996, she moved to the National Institutes of Health in Bethesda, Maryland, in the Laboratory of Chemoprevention directed by Michael B. Sporn. The following year, she went to the Laboratory of Molecular Microbiology directed by Malcolm A. Martin as a Visiting Associate. In 1993 she was back in Italy, at the IRCCS San Raffaele in Milan, where she co-founded the AIDS Immunopathogenesis Unit, together with Guido Poli. Since 2006, she is the director of the Biosecurity and Viral Pathogens Unit.
Come ogni anno, con il sopraggiungere della stagione invernale, saremo esposti ai virus influenzali che causeranno problemi di salute e significative perdite economiche per aziende pubbliche e private. In una piccola, ma non trascurabile percentuale, ci saranno complicazioni e, potenzialmente, anche un aumento della mortalità tra neonati e anziani causati dagli stessi virus.